{"doi":"10.3390/cancers14092156","title":"MiR-150-5p Overexpression in Triple-Negative Breast Cancer Contributes to the In Vitro Aggressiveness of This Breast Cancer Subtype","abstract":"MiR-150-5p is frequently deregulated in cancer, with expression and mode of action varying according to the tumor type. Here, we investigated the expression levels and role of miR-150-5p in the aggressive breast cancer subtype triple-negative breast cancer (TNBC). MiR-150-5p expression levels were analyzed in tissue samples from 113 patients with invasive breast cancer (56 TNBC and 57 non-TNBC) and 41 adjacent non-tumor tissues (ANT). Overexpression of miR-150-5p was observed in tumor tissues compared with ANT tissues and in TNBC compared with non-TNBC tissues. MiR-150-5p expression levels were significantly associated with high tumor grades and the Caucasian ethnicity. Interestingly, high miR-150-5p levels were associated with prolonged overall survival. Manipulation of miR-150-5p expression in TNBC cells modulated cell proliferation, clonogenicity, migration, and drug resistance. Manipulation of miR-150-5p expression also resulted in altered expression of its mRNA targets, including epithelial-to-mesenchymal transition markers, MYB, and members of the SRC pathway. These findings suggest that miR-150-5p is overexpressed in TNBC and contributes to the aggressiveness of TNBC cells in vitro.","journal":"Cancers","year":2022,"id":248863,"datarank":0.5101796072493234,"base_score":3.4011973816621555,"endowment":3.4011973816621555,"self_citation_contribution":0.5101796072493234,"citation_network_contribution":0.0,"self_endowment_contribution":0.5101796072493234,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":29,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.949,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":888460,"name":"Yara Rodríguez","orcid":"0000-0002-4121-5740","position":1,"is_corresponding":false},{"id":336217,"name":"Aline Simoneti Fonseca","orcid":"0000-0002-0840-8487","position":2,"is_corresponding":false},{"id":888933,"name":"Emanuelle Nunes Souza","orcid":null,"position":3,"is_corresponding":false},{"id":264146,"name":"Bhaskar Kallakury","orcid":"0000-0002-1298-2983","position":4,"is_corresponding":false},{"id":338103,"name":"Iglenir João Cavalli","orcid":null,"position":5,"is_corresponding":false},{"id":888461,"name":"Enilze Maria de Souza Fonseca Ribeiro","orcid":"0000-0002-2194-4727","position":6,"is_corresponding":false},{"id":371123,"name":"Ritu Aneja","orcid":"0000-0003-4489-5320","position":7,"is_corresponding":false},{"id":336221,"name":"Luciane R. Cavalli","orcid":"0000-0001-5619-9037","position":8,"is_corresponding":false},{"id":737646,"name":"Bruna M. Sugita","orcid":"0000-0001-7599-3826","position":0,"is_corresponding":true}],"reference_count":79,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T00:24:14.794521Z","pmid":"35565284","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}